1 / 59

# Statistics for Clinical Trials in Neurotherapeutics - PowerPoint PPT Presentation

Statistics for Clinical Trials in Neurotherapeutics. Barbara C. Tilley, Ph.D. Medical University of South Carolina. Funding:. NIA Resource Center on Minority Aging 5 P30 AG21677. NINDS Parkinson’s Disease Statistical Center U01NS043127 and U01NS43128. Sample Size.

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.

## PowerPoint Slideshow about ' Statistics for Clinical Trials in Neurotherapeutics' - ingrid

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

### Statistics for Clinical Trials in Neurotherapeutics

Barbara C. Tilley, Ph.D.

Medical University of South Carolina

NIA Resource Center on Minority Aging

5 P30 AG21677

NINDS Parkinson’s Disease Statistical Center

U01NS043127 and U01NS43128

• What is the outcome?

• How will this be measured

• One or many measures of outcome?

• How will you analyze the data?

• (Nquery \$700, STPLAN free, etc.)

Sample Size: Putting it all together

Continuous (Normal) Distribution

Need all but one: , , 2, , N

Z = 1.96 (2 sided, 0.05);

Z = 1.645 (always one-sided, 0.05,

95% power)

 = difference between means

2= pooled variance

+

)

s

4(Z

Z

2

2

a

b

=

2n

d

2

• 10% dropout, increasing sample size by 10% is not enough

• Use: 1/(1-R)2

Friedman, Furburg, DeMets

• Choose largest

sample size for any

single outcome.

• If multiple aims, use

largest sample size for

any aim.

Sample Size: Food for Thought

• Is detectable difference biologically/clinically meaningful?

• Is sample size too small to be believable? WHERE DID YOU GET the estimate????

• Report power (for design), not conditional power for negative study.

Sample Size: Keeping It Small

• Study continuous outcome

(if variability does not increase)

• Updrs Score rather “above or below cut-point”

• Study surrogate outcome where

effect is large

• Rankin at 3 months rather than stroke mortality

• Reduce variability (ANCOVA, training, equipment, choosing model)

Sample Size: Keeping It Small

• Difference between two means = 1

• Standard deviation = 2;

N = 64/group

• Standard deviation = 1;

N = 17/group

• Parametric?

• Normal

• Binomial

• Nonparmetric?

• Ranked

Sample size to detect effect of size

observed in NINDS t-PA Stroke Trial

Barthel:

• Non-parametric N = 507

• Binary N = 335

Rankin:

• Non-parametric N = 394

• Binary N = 286

• Different questions, can argue

• Effect on blood pressure

• Effect on quality of life

• All pair-wise comparisons or

multiple measures of same

• Pairwise comparisons of

Drugs A, B, C (same outcome)

Multiple Comparisons

• Bonferroni (or less conservative Simes, or Hockberg)

• /#tests = 0.05/5 = 0.01

• Sample size, use adjusted 

• ANOVA methods – Tukey’s, etc.

• Sample size for ANOVA

• All outcomes measure same construct

• Stroke recovery

• PD progression

• May lack power when most measures of efficacy are improved, but no single measure is overwhelmingly so.

• Problem exacerbated when outcomes are highly correlated.

• No one outcome sufficient or desirable

• Outcome is difficult to measure and combination of correlated outcomes useful

Properties of Global Test

• If all outcome measures perfectly correlated,

• test statistic, p-value same as for single (univariate) test

• power = power of univariate test

• Assumes common dose effect

• Power increases as correlation among outcomes decreases

O’Brien’s Non-parametric Procedure (Biomet., 1984)

• Separately rank each outcome in the two treatment groups combined.

• Sum ranks for each subject.

• Compare mean ranks in the two treatment groups using

• Wilcoxon or t-test

• ANOVA if more than two treatments

Sample Size forGlobal Test

• Use largest sample size for single outcome

Randomization Binary Outcomes

Randomization Binary Outcomes

• Stratification

• Age, prior stroke, years with PD, site

• Greatest gain if N < 20

• Too many strata, difficult to balance

• 3 age x 2 years with PD x gender = 12

• Blocking – balance number in each treatment group

• Important if number expected per site is small

• Minimization

• Can be complicated to implement, cause delays

Interim Analyses Binary Outcomes

• Who?

• Why?

• When?

• How?

Stopping “Guidelines” Binary Outcomes

5.0

3.0

2.0

-2.0

-3.0

-5.0

Reject Ho

• O’Brien-Fleming

• Pocock

• Peto

Continue

Fail to Reject Ho

0

Standard Normal Statistic (Zi)

Reject Ho

# Looks

1 2 3 4 5

Intent-to-Treat (ITT) Binary Outcomes

Intent-to-treat means analyzing

ALL patients as randomized.

• Patients lost to follow-up (LTF)

• Patients who do not adhere to treatment

• Patients who were randomized and did not receive treatment

• Patients incorrectly randomized

Imputation Binary Outcomes

• Definition - replacing a value for those lost to follow-up or not adhering.

• Imputation may or may not be ITT.

Optimal Approach Binary Outcomes

MAKE IMPUTATION UNECESSARY!

Optimal Approach Continued Binary Outcomes

• Make follow-up a high priority

• Monitor follow-up closely

• Build in patient incentives

• “gifts” for patients (t-shirts, mugs, etc.)

• free parking, meal ticket

• Transportation

• Follow even those off treatment

Hypertension Detection and Follow-up Program/MRFIT Binary Outcomes

• Outcome was mortality

• HDFP 21/10,940

• MRFIT 30/12,866

• Used Death Index, Social Security, detectives

NINDS t-PA Stroke Trial Binary Outcomes

• Four 3-month outcomes

• Barthel,NIHSS,GOS, Rankin

• NINDS Project Officer pushed for complete ascertainment

• Study staff made house calls, searched medical records

• 5/612 (<1%) lost to follow-up on at least one of the four outcome measures

• Used worst value possible

NET-PD Futility Studies Binary OutcomesLTF for 1-year outcome(Used worst outcome in assigned group)

• FS-1 3/200

• Creatine 2

• Minocycline 0

• Placebo 1

• FS-2 4/213

• GPI 3

• CoQ10 1

• Placebo 0

Handling Missing Values Binary Outcomes

• Why?

• How?

When Data Are Missing: Binary OutcomesCommon Approaches

Subgroup Analyses Binary Outcomes (Sub-set)

• Pre-specified based on rationale

• NINDS t-PA Stroke Trial

• Those randomized 0-90 minutes and 91-180 minutes from stroke onset

• Post-hoc in the presence of interaction

• (Yusuf, 1991)

Subgroup Analyses Binary Outcomes

• The more subgroups examined, the more likely analyses will lead to finding a difference by chance alone.

• 10 mutually exclusive subgroups;

• 20% chance that in one group the treatment will be better than control and that the converse will be true in another

Example of Interaction Binary Outcomes(Effect Modification)

Lack of Interaction Binary Outcomes

Trial of Org10172 for Stroke (TOAST) Trial Binary Outcomes

N = 379(M) 238 (F) N=372(M) 239 (F)

Test for interaction p = 0.251

Pooled Analysis Binary OutcomesCarotid Endarterectomy

Rothwell, 2004 NASCET &ECST

N (men) 4175 N(women) 1718 Test for interaction p = 0.007 (Cox model)

Pooled Analysis Binary OutcomesECASS, Atlantis, NINDSKent 2005

N (men) 4175 N(women) 1718 Test for interaction p = 0.04 (logistic model)

References Binary Outcomes

• Rubin, DB. More powerful randomization-based p-values in double blind trials with non-compliance. Statistics in Medicine (1998) 17:317-385.

• Little R, Yau L. Intent-to-treat analysis for longitudinal studies with drop-outs. Biometrics (1996) 52:1324-1333.

• NINDS t-PA Stroke Trial Study Group. Tissue Plasminogen Activator for Acute Stroke (1995) 333:1581-1587.

• Curb JD, et al. Ascertainment of vital status through the national death index and social security administration. A J Epi (1985)121:754-766.

• Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial: risk factor changes and mortality results. JAMA (1982) 248:1466-77.

Completers Binary Outcomes

• Retain only those patients who remain on treatment

• Was used frequently in past in trials in rheumatoid arthritis

• Not intent-to-treat

• Obvious potential for bias

• patients not responding to treatment drop-out

Last Observation Carried Forward Binary Outcomes

• For those missing a final value, use most recent previous observation.

• Potential for bias in disease with downward course

Worst case Binary Outcomes

• Replace missing values with worst outcome

• assumes that those who are lost to follow-up were not successfully treated

• generally variance is not inflated

• could inflate or deflate differences

Best Case/Worst Case Binary Outcomes

• Replace missing values in treatment group by worst outcome and missing values in comparison group with best outcome.

• Rarely used

• Generally overly conservative as both treatment and placebo group drop-out for lack of efficacy.

Missing at Random Binary Outcomes

• Drop-out at time t does not depend on unobserved outcomes at times t’> t, after conditioning on data up to time t.

• Example:

• a patient misses follow-up visit because she is not feeling well (small TIA’s) then has a major stroke a week later.

Missing at random Binary Outcomes

• Ignore missing values

• In survival analyses, censor at date of last follow-up

• Use generalized estimating equations

• Difficulties in assessing missing at random

• Rarely is this assumption expected

Rubin’s Approach for Non-Compliance Binary Outcomes

• Assume assignment to treatment (T) or control (C) has no effect on outcome for non-complying patients.

• Model compliance status under the null hypothesis (no effect on outcome)

• Compute average effect of assignment to T versus C for subset of T compliers.

Rubin’s Approach Continued Binary Outcomes

• Few studies have “pure” non-compliers.

• Pure non-compliers

• those refusing surgery in surgical trial

• those refusing medication after randomization

• If patients take some medication, there may be carryover treatment effects

Little’s Approach to Imputation Binary Outcomes

• Uses multiple imputation for patients who are missing information based on actual dose after drop-out if known or assumption.

• Accounts for uncertainty in parameter estimates.

• Model parameters drawn from posterior distn’, then missing values drawn from predictive distn’ conditional on drawn parameters.

Geller, et al Binary Outcomes

• Raynaud’s Treatment Study

• Model missing values using patient covariates at baseline to identify similar patient(s) with follow-up (neighbor)

• Weights neighbor, sets weight for missing patient to zero

• (Propensity Score)

LTF Groups And Imputation Methods Binary Outcomes